Medically Reviewed By
— Written By
— Updated on September 16, 2026
On this page
“Exosome IV therapy” is one of the highest-volume search terms bringing physicians to information about extracellular vesicle products, and one of the least served by careful writing. Most of what ranks for it is either a clinic’s own marketing or a forum thread. Almost none of it is written for a physician trying to decide, before anything is ordered or administered, whether the decision can be defended.
This piece does not describe a protocol. It does not recommend intravenous administration of any exosome product, and it does not evaluate whether IV delivery performs better or worse than any other route for any condition. It is a due-diligence checklist: the questions a physician should be able to answer, from regulatory footing to the paperwork behind the vial, before systemic administration is even on the table. Where the literature is preclinical, this says so. Where a question is the physician’s own to answer, this says that too.
Why Systemic Administration Is a Different Question Than Local Application
Local or topical application of a research material and systemic administration are not the same risk category. The difference isn’t a matter of degree. It’s a difference in what happens to the material once it leaves the point of contact.
A 2025 PET-imaging biodistribution study compared subcutaneous, intraperitoneal, and intravenous administration of stem cell-derived exosomes labeled with a radioactive tracer, side by side, in an animal model. The three routes did not produce the same result. Subcutaneous administration kept most of the tracer at the injection site for well over a week. Intraperitoneal administration concentrated it in the stomach and spleen. Intravenous administration was the outlier: within the first hour, radioactivity was already measurable in the lungs, liver, and spleen simultaneously, and it stayed detectable across all three organs through the full 48-hour observation window. Rapid, multi-organ distribution, not containment near a delivery site. That pattern holds up against the broader biodistribution literature on systemically administered exosomes generally.
What that means for a provider evaluating the question is straightforward: once a research material enters systemic circulation, exposure is no longer confined to whatever tissue a physician intended to reach. Liver, spleen, lungs: organs with no bearing on the research question at hand receive material by default, not by design. That’s a pharmacokinetic fact about the delivery route, not a claim about any product’s safety profile. It’s exactly the kind of fact a physician should be able to speak to before systemic administration of any biological material is under consideration, research or otherwise.
It also means the questions shift with the route. A topical or local research application raises questions about tissue-level handling and local reaction. Systemic administration raises a different set: what happens to material in organs that were never the intended target, what the immune system’s exposure looks like at that scale, and what dose and clearance data exist for the specific batch a physician is actually holding, not for exosomes as a category.
Systemic exposure also raises immune considerations that local application does not. Exosomes carry surface proteins recognized by the reticuloendothelial system, part of why they accumulate preferentially in organs built to filter circulating particulate matter. A physician weighing systemic administration is implicitly asking the immune system to process material at a scale and location a local application never would. Whether that matters for a specific product depends on characterization data a supplier should be able to produce, not on assumption in either direction.
What Documentation Should Exist Before Any Administration Decision
None of what follows is a recommendation to proceed. It’s the documentation a provider should already have in hand, or should recognize is missing, before administration of any kind is a live question.
Batch-specific testing, not category-level marketing. A certificate of analysis for the specific lot in question should confirm identity, purity, sterility, and potency for that batch, not for the product line in general. A supplier who can produce a COA on request but can’t tie it to the batch number on the vial in front of a physician hasn’t actually answered the question.
The physician’s own regulatory standing. What applies in a given jurisdiction, and to that physician’s own license, is a legal question. The physician, and where appropriate their own counsel, needs to settle it for themselves. A supplier’s marketing copy can’t settle it on their behalf. That includes understanding which appropriate regulatory frameworks apply to research-use material in the jurisdiction where administration would occur, and whether an IND pathway or equivalent applies to the specific use under consideration. [CellGenic’s regulatory status update](URL-TBD: regulatory-status-update) tracks how these frameworks are shifting, but it isn’t a substitute for a physician’s own legal review, and CellGenic does not provide legal or regulatory advice.
Institutional and ethical review. Systemic administration of a research-use biological material is the kind of decision that, in most institutional settings, doesn’t rest on one physician’s judgment alone. Whether an institutional review process, an ethics committee, or an equivalent internal mechanism has weighed in, and whether that review is documented, is something a physician should be able to answer before the fact, not after it.
Informed consent that reflects the actual designation of the material. Consent language that describes a research-use-only product as though it were an approved therapeutic misrepresents what a patient is actually being asked to accept. A consent process should establish that the material isn’t approved for human administration outside the research context in which it’s being used, what is and isn’t known about it, and what alternatives exist. Drafting that language is a matter for the physician’s own institutional and legal counsel. CellGenic does not supply consent language, and this article doesn’t attempt to either.
A documented chain of custody. Cold-chain handling, storage conditions, and time from thaw to administration all affect the material a physician is actually working with by the time it reaches a patient. That’s separate from whatever the COA said about the batch when it left the supplier. A provider should be able to reconstruct that chain for any single administration event, not just describe it in general terms. [CellGenic’s Certificate of Analysis guidance](URL-TBD: coa-reading-guide) covers what should be documented at the point the batch leaves the supplier; chain of custody after that point is the provider’s own record to keep.
Sourcing Questions a Physician Should Be Able to Answer
The questions above concern documentation a provider should hold. These concern the supplier providing it.
What characterization method was used, and does it match current reporting standards? MISEV, the field’s current consensus framework maintained by the International Society for Extracellular Vesicles, specifies what a legitimate characterization report should include: particle concentration and size distribution by a validated method (commonly nanoparticle tracking analysis), protein markers confirming exosomal identity, and a stated isolation method. A supplier who can’t describe which of these were run, and by what method, can’t support a systemic-administration decision with data. Only with a label.
Is testing performed per batch, or once per product line? These aren’t the same claim. Per-batch testing means the vial in a physician’s hand was tested. Product-line testing means a representative sample once was. A supplier’s marketing language rarely distinguishes the two, and a physician evaluating systemic use should ask directly rather than infer it from a COA’s letterhead.
What manufacturing environment produced this batch? cGMP manufacturing and a controlled cleanroom environment (commonly referenced as ISO 14644-1 Class 7, sometimes shortened to “ISO 7”) are claims about the facility, not the product’s characterization data. Both matter. A supplier should speak to each separately rather than treat one as a stand-in for the other.
Where did the source material come from, and is that origin itself documented? Tissue or cell source, donor screening, and isolation method all affect what’s actually in a given exosome preparation. A physician should be able to trace a batch back to a documented source, not a general description of the product category.
What does the supplier say about route of administration specifically? A supplier who characterizes a product for research use broadly, without addressing what is and isn’t known about systemic administration specifically, has left the highest-exposure question unanswered. That question belongs to the supplier’s documentation as much as to the physician’s own literature review. Reviewing what to consider when evaluating an exosome supplier before any sourcing decision is made covers most of the ground above in more detail.
Can documentation be produced per batch, on request, tied to a specific lot number, not just made available as a general quality statement? None of these questions has a single right answer that applies across every research context. What they share: a physician should be able to answer all of them for a specific batch of a specific product before systemic administration is a live question, rather than rely on a supplier’s general reputation to answer them by proxy.
The Honest State of the Evidence for Systemic Administration
The clinical evidence base for exosome products is still early, across every route of administration. Intravenous is, counterintuitively, already the most common route among registered trials rather than the least. A 2026 analysis of the global clinical-trial registry for human-derived extracellular vesicles found that intravenous administration accounts for roughly a third of registered interventional trials, ahead of other delivery routes. Only three trials worldwide, out of close to 150 identified, had reached Phase III. That gap says nothing about any individual product’s safety or efficacy. It says a great deal about how early-phase the field’s own clinical evidence still is, for this route specifically.
That distinction matters for how a physician reads anything else written about exosome IV administration, including this article. Early-phase trial registration means a research question is being asked in a controlled setting, with prospective protocols, eligibility criteria, and safety monitoring built in from the start. It doesn’t mean systemic administration of exosome products is established practice, or that the risk profile for any specific product outside that controlled setting is known. A registered Phase 1 trial and a physician’s individual decision to administer a product systemically sit in different categories of activity, even when the material involved looks similar on paper.
A physician should be candid with themselves here about what they are and aren’t replicating. A trial’s inclusion criteria, monitoring protocol, adverse-event reporting infrastructure, and institutional oversight aren’t incidental. They’re a large part of why a Phase 1 finding means what it means, and none of that infrastructure travels with a vial.
A supplier’s documentation speaks to what a batch contains. Whether the field has established anything about administering that category of material systemically is a separate question, and it remains the physician’s own responsibility to have read that literature. The [safety review for exosome-derived research material](URL-TBD: exosome-safety-review) is one place to start, though it addresses characterization and handling risk rather than the administration-route question this article is built around.
Common Questions
No. This is a due-diligence overview of the documentation, sourcing questions, and evidence a physician should review before systemic administration is under consideration, not a protocol and not instructions for administration. Any decision to administer any research material remains the sole responsibility of the licensed physician, under applicable law and their own institutional review.
Yes, at the level of basic biodistribution. Preclinical data show that systemically administered exosomes distribute rapidly across multiple organs, commonly the liver, spleen, and lungs, rather than remaining localized to a delivery site. That isn't the case for topical or local application.
Registered interventional trials exist, and intravenous is currently the most common administration route among them. But the overall field remains early-phase: only a small number of trials globally have reached Phase III for extracellular-vesicle products across any route. Physicians should treat this as an active, unsettled research area, not an established practice.
No. CellGenic supplies research-grade material with batch-specific documentation. Protocols, consent language, and the clinical decision to administer any product remain the physician's own responsibility, developed with their own institutional and legal counsel.
At minimum: what characterization method was used and against what reporting standard, whether testing is performed per batch or per product line, what manufacturing environment produced the batch, and whether documentation can be tied to a specific lot number on request.
REGULATORY DISCLAIMER · EXOSOMES
These products are intended for laboratory research use only. They are not drugs, foods, cosmetics, or medical treatments and must not be used for any form of human or animal administration. All information provided is for educational and scientific reference only and the products should be handled exclusively by licensed, qualified professionals. Misbranding, misuse, or mislabeling of these products as therapeutic or consumable substances is strictly prohibited by law.
